Funding sources None.
DERMATOLOGICAL SURGERY AND LASERS
Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study
Article first published online: 21 MAY 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 167, Issue 1, pages 110–115, July 2012
How to Cite
van der Geer, S., Martens, J., van Roij, J., Brand, E., Ostertag, J.U., Verhaegh, M.E.J.M., Neumann, H.A.M. and Krekels, G.A.M. (2012), Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. British Journal of Dermatology, 167: 110–115. doi: 10.1111/j.1365-2133.2012.10924.x
Conflicts of interest None declared.
- Issue published online: 28 JUN 2012
- Article first published online: 21 MAY 2012
- Accepted manuscript online: 3 MAR 2012 10:00AM EST
- Accepted for publication 26 February 2012
Background Imiquimod 5% cream can reduce or clear superficial and small nodular basal cell carcinoma (BCC). It could be used as a pretreatment of Mohs micrographic surgery (MMS) to decrease defect size.
Objectives To study if a pretreatment with imiquimod 5% cream decreases defect size after MMS. In addition, to study the effect on the number of Mohs stages and reconstruction time.
Methods Seventy patients aged >18 years with a primary nodular BCC in the face were included. The imiquimod group used imiquimod 5% cream for 4 weeks, before MMS. The control group was treated with MMS only. Tumour and defect sizes were measured. We noted the number of Mohs stages, reconstruction time and side-effects.
Results The median percentage increase in area from tumour size at baseline to the post-MMS defect for the imiquimod group was significantly less compared with the control group, 50% vs. 147% (P < 0·001). A tendency towards fewer Mohs stages in the imiquimod group was observed and the reconstruction time was significantly shorter in this group (P = 0·01).
Conclusions Imiquimod 5% cream as pretreatment of MMS significantly reduced the tumour size in primary nodular BCC and reduced the surgical defect size. Further research is necessary to investigate cost-effectiveness.